Somatropin Found Less Effective Than Somatrogon, a Long-Acting Human Growth Hormone Molecule, in Treatment of Growth Hormone Deficiency
Somatropin
is a protein synthetic hormone that is commonly used in injecting it to the
body to induce puberty. It is produced by the pituitary gland and the secretion
of this hormone causes the enlargement of tissues and muscles. This hormone is
found in higher levels during childhood and gradually decreases with the
person's age. This allows the person to develop leaner and muscular muscles. It
helps in improving bone strength and density and also helps in reducing fat.
Production
of somatropin is stimulated by the secretion of the hormone receptor cells,
which are present both in the anterior pituitary gland and the anterior
suprachiasmatic nucleus. Somatropin or growth hormone, also called human growth
hormone in its pure human form, is basically a peptide hormone, which
stimulates cell growth, cell repair, and cell metabolism in humans and many
other animals as well. It is therefore extremely important in human growth and
development.
Somatropin has its own receptor called igf-1, which is present
both in the anterior pituitary gland and the anterior suprachiasmatic nucleus.
The hormone gets released from the pituitary gland into the bloodstream. It
then travels to the brain where it passes through a complicated series of
receptor binding steps before reaching the site of action. Here it releases its
active ingredients or hormones, which cause changes in various cells and
tissues in the body. The release of this hormone is timed by a particular body
panel which includes the anterior pituitary gland, the anterior suprachiasmatic
nucleus, and the brain. After releasing the hormones somatropin travels back to
the pituitary gland where it is again processed and injected back into the
body.
In
recent studies, somatrogon, a long-acting human growth hormone (hGH) molecule,
has shown more efficacy compared to somatropin in the treatment of pediatric
patients with growth hormone deficiency. In February 2021, the European
Medicines Agency validated for review the Marketing Authorization Application of
Pfizer Inc., the U.S.-based pharmaceutical company, and OPKO Health Inc. for
somatrogon, a long-acting recombinant human growth hormone that is intended to
be administered once-weekly for the treatment of pediatric patients with growth
hormone deficiency.
Comments
Post a Comment